Latest Articles and Analysis

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

Pharmaceutical industry changes to 340B implementation impact pricing and accessibility for covered entities.

AMA survey: 93% of providers say prior authorizations delay care with 91% reporting negative clinical impact.

Medication abandonment disproportionately affects Black patients; PrEP users 41% more likely to abandon.

Copay accumulator programs block patient assistance from counting toward deductibles; HELP Copays Act needed.

FDA extends Cabenuva to 2-month injections but insurance barriers continue to restrict patient access.

MAT Act removes X-waiver requirements, expanding buprenorphine access especially in rural communities.

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

CANN announces 2022 organizational changes including rebranding and launching the 340B Action Center.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

Analyzes the role of contract pharmacies and intermediaries in 340B drug distribution and patient access.

Examines how 340B program expansion correlates with declining hospital charity care for vulnerable patients.

Explores accountability mechanisms in the 340B program and oversight requirements for patient protection.

Explains why transparency in 340B operations is critical for program integrity and patient access.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

Introduces the 340B Drug Discount Program: its history, purpose, and significance for medication access.

Payers restrict HCV treatment through utilization management; patient assistance programs fill the critical gap.

Analyzes CMS marketplace rule changes and Medicaid expansion risks as pandemic emergency declarations end.

31,000 Veterans with HIV face unique barriers including comorbidities and HCV rates 3x the general population.

Analyzes Biden health policy priorities including drug pricing reform and Medicare expansion.